Tm Bioscience Licenses CYP450 SNP in Bid for 510(k) to Rival Roche; Also Plans Warfarin Dx | GenomeWeb

Tm Bioscience is gearing up to take on Roche Molecular Diagnostics' AmpliChip CYP450 assay, and it hopes to produce a diagnostic to help guide dosing with the anticoagulant warfarin, which may rival a test being developed by Third Wave Technologies.

"Our goal is to take all of those assays â€" and we'll have five cytochrome P450 assays, including the warfarin assay â€" and we intend to submit four of them this year for FDA approval," said Tm Bioscience CEO Greg Hines in an interview with Pharmacogenomics Reporter last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.